GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (FRA:NV3P) » Definitions » Cyclically Adjusted Book per Share

Nanoviricides (FRA:NV3P) Cyclically Adjusted Book per Share : €5.44 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Nanoviricides Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Nanoviricides's adjusted book value per share for the three months ended in Mar. 2024 was €0.830. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €5.44 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Nanoviricides's average Cyclically Adjusted Book Growth Rate was -6.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -0.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Nanoviricides was 12.60% per year. The lowest was -0.70% per year. And the median was 3.20% per year.

As of today (2024-06-20), Nanoviricides's current stock price is €1.50. Nanoviricides's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €5.44. Nanoviricides's Cyclically Adjusted PB Ratio of today is 0.28.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nanoviricides was 0.55. The lowest was 0.00. And the median was 0.00.


Nanoviricides Cyclically Adjusted Book per Share Historical Data

The historical data trend for Nanoviricides's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoviricides Cyclically Adjusted Book per Share Chart

Nanoviricides Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.59 1.01 5.51 6.55 6.07

Nanoviricides Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.81 6.07 6.26 5.82 5.44

Competitive Comparison of Nanoviricides's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Nanoviricides's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoviricides's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoviricides's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nanoviricides's Cyclically Adjusted PB Ratio falls into.



Nanoviricides Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nanoviricides's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.83/131.7762*131.7762
=0.830

Current CPI (Mar. 2024) = 131.7762.

Nanoviricides Quarterly Data

Book Value per Share CPI Adj_Book
201406 6.297 100.560 8.252
201409 10.109 100.428 13.265
201412 8.748 99.070 11.636
201503 10.302 99.621 13.627
201506 9.894 100.684 12.949
201509 9.502 100.392 12.473
201512 9.011 99.792 11.899
201603 7.428 100.470 9.743
201606 7.050 101.688 9.136
201609 6.191 101.861 8.009
201612 6.208 101.863 8.031
201703 6.642 102.862 8.509
201706 5.713 103.349 7.284
201709 4.905 104.136 6.207
201712 4.244 104.011 5.377
201803 4.500 105.290 5.632
201806 4.371 106.317 5.418
201809 3.946 106.507 4.882
201812 3.500 105.998 4.351
201903 2.932 107.251 3.602
201906 2.440 108.070 2.975
201909 2.151 108.329 2.617
201912 1.796 108.420 2.183
202003 1.688 108.902 2.043
202006 2.127 108.767 2.577
202009 2.387 109.815 2.864
202012 2.136 109.897 2.561
202103 2.328 111.754 2.745
202106 2.156 114.631 2.478
202109 2.088 115.734 2.377
202112 2.031 117.630 2.275
202203 1.946 121.301 2.114
202206 1.884 125.017 1.986
202209 1.876 125.227 1.974
202212 1.612 125.222 1.696
202303 1.459 127.348 1.510
202306 1.173 128.729 1.201
202309 1.035 129.860 1.050
202312 0.969 129.419 0.987
202403 0.830 131.776 0.830

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Nanoviricides  (FRA:NV3P) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Nanoviricides's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.50/5.44
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nanoviricides was 0.55. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Nanoviricides Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Nanoviricides's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoviricides (FRA:NV3P) Business Description

Industry
Traded in Other Exchanges
Address
1 Controls Drive, Shelton, CT, USA, 06484
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Nanoviricides (FRA:NV3P) Headlines

No Headlines